FDA Approved: INFLIXIMAB — Supplemental Application (Janssen Biotech, Inc.)

View source ↗

Summary

The FDA approved a supplemental application for infliximab (Remicade) from Janssen Biotech, Inc., updating the product labeling per the supplemental submission.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ankylosing Spondylitis
• Crohn Disease
• Juvenile Idiopathic Arthritis
• Plaque Psoriasis
• Psoriatic Arthritis
• Rheumatoid Arthritis
• Ulcerative Colitis

Drugs mentioned

• Remicade (infliximab)

Snippet

SUPPL AP for INFLIXIMAB (INFLIXIMAB)